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Abstract
Accurate and reliable quantification of the abundance of mitochondrial DNA
(mtDNA) molecules, both wild-type and those harbouring pathogenic mutations, is
important not only for understanding the progression of mtDNA disease but also for
evaluating novel therapeutic approaches. A clear understanding of the sensitivity of
mtDNA measurement assays under different experimental conditions is therefore
critical, however it is routinely lacking for most published mtDNA quantification
assays. Here, we comprehensively assess the variability of two quantitative
Taqman real-time PCR assays, a widely-applied MT-ND1/MT-ND4 multiplex
mtDNA deletion assay and a recently developed MT-ND1/B2M singleplex mtDNA
copy number assay, across a range of DNA concentrations and mtDNA deletion/
copy number levels. Uniquely, we provide a specific guide detailing necessary
numbers of sample and real-time PCR plate replicates for accurately and
consistently determining a given difference in mtDNA deletion levels and copy
number in homogenate skeletal muscle DNA.
Introduction
The mitochondrial genome (mtDNA) is a multicopy 16.5 kb circular, double-
stranded DNA molecule that encodes 13 essential subunits of the mitochondrial
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respiratory chain, as well as 22 mt-tRNAs and two mt-rRNAs necessary for their
synthesis. A wide variety of phenotypically heterogeneous diseases, frequently
involving the neuromuscular system [1], are associated with mtDNA mutations
and/or changes in the cellular abundance of mtDNA molecules. MtDNA
mutations can vary from point mutations through to extensive genomic
rearrangements, with large-scale mtDNA deletions occurring in approximately
13% of patients with mtDNA disease [2]. Both mutated and wild-type forms of
mtDNA can coexist within a cell, a situation termed heteroplasmy. When
mutation loads exceed a critical threshold level within an individual cell (typically
.60%), a biochemical defect, most often a deficiency in the activity of
cytochrome c oxidase (COX), can be detected [3]. The overall number of mtDNA
molecules present can also influence a cell’s respiratory capacity. A quantitative
loss of mtDNA copy number of more than 30% of wild-type level has been linked
to multisystemic mitochondrial disease [4]. Conversely, an increase in mtDNA
abundance can represent a compensatory response to inefficient mitochondrial
respiratory function [5].
A key requirement in mtDNA disease research is thus the quantification of
mtDNA molecules, both wild-type molecules and those harbouring pathogenic
mutations. These measurements must be accurate and reliable, particularly to
enable the detection of small differences in mtDNA abundance and integrity in
homogenate tissues. This is of crucial importance for elucidating the molecular
mechanisms involved in mtDNA pathologies and their clinical progression.
Moreover, it is vital for determining the value of novel therapeutic approaches,
such as endurance and resistance exercise training regimes [6–9].
At present, the most commonly employed technology for the quantitative
analysis of mtDNA molecules is real-time PCR. A variety of assays have been
published (e.g. singleplex, multiplex, three primer assay), differing in the nuclear
and mitochondrial genomic locations they target and the real-time chemistries
they exploit [10–17]. To the best of our knowledge a comprehensive assessment of
the sensitivity of each of these assays, including our own previously described MT-
ND1/MT-ND4 and MT-ND1/B2M assays [11, 18, 19], has never been published.
This characterisation is particularly important in light of a recent report on the
effect of DNA concentration on measurement error in real-time PCR assays,
which describes how empirical error increases as DNA concentration decreases
[20]. Moreover, the relationship between sample heteroplasmy and real-time assay
sensitivity has never been investigated, despite indications that measurement error
increases as deleted mtDNA levels decrease [11].
Here, we detail the variability present in our Taqman MT-ND1/MT-ND4 real-
time PCR assay with respect to two variables: the DNA concentration of
homogenate skeletal muscle samples and the level of deleted mtDNA. We also
characterise the sensitivity and reproducibility of a Taqman mtDNA copy number
assay, which targets MT-ND1 and the nuclear B2M gene in separate reactions,
under different DNA concentration and copy number conditions. Finally,
guidelines for achieving the most accurate and reliable mtDNA measurements at
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these different levels of mtDNA deletion/copy number and DNA concentration in
homogenate skeletal muscle are provided.
Materials and Methods
This study had relevant ethical approval from the institutional review board of
Newcastle University and complied with the Declaration of Helsinki. Written
informed consent was obtained from all patients involved.
DNA samples and handling
DNA samples originated from patients harbouring different loads of single, large-
scale mtDNA deletions (6–84% mutant load; n56) and from control individuals
(n53) with varying mtDNA copy numbers (Table 1). Total DNA had been
extracted from skeletal muscle (quadriceps) needle biopsies (approximately 10 mg
tissue) using the EZ1 DNA Tissue extraction kit (Qiagen, Crawley, UK), as per the
manufacturer’s recommendations. DNA concentrations were determined using a
Nanodrop ND-1000 UV-Vis spectrophotometer (Thermo Fisher Scientific). DNA
samples were stored at 4 C˚ for the duration of the study (up to 1 month) to avoid
freeze-thaw artefacts. The preservation of DNA integrity over this time period was
confirmed by agarose gel electrophoresis (Figure S1). All DNA dilutions were
systematically performed in 10-fold serial dilution steps, with pipette tips being
flushed out 20 times prior to pulse-vortexing the DNA on a medium setting for
15 seconds between each dilution.
Mitochondrial DNA deletion assay
The proportion of deleted mtDNA was determined using the previously described
multiplex MT-ND1/MT-ND4 Taqman real-time PCR assay [11] on a StepOne
Plus real time machine (Applied Biosystems, Warrington, UK), with the following
modifications. Reactions were performed in 20 ml volumes. Probes were designed
with a non-fluorescent quencher and MGB moiety: MT-ND1 probe VIC-
59CCATCACCCTCTACATCACCGCCC-39-MGB (revised Cambridge Reference
Sequence (rCRS) location m.3506-3529; GenBank accession number
NC_012920.1) and MT-ND4 probe FAM-59-
CCGACATCATTACCGGGTTTTCCTCTTG-39-MGB, rCRS location m.12111-
12138). Standard curves were included for analysis of data. To minimise pipetting
error, DNA from single deletion mtDNA patients was added to each well in 5 ml
volumes. Intra-plate variance was investigated using the single mtDNA deletion
patient DNA samples at a minimum of three different concentrations (with final
PCR DNA concentrations ([DNA]PCR) ranging between 0.1 ng/ml and 0.1 fg/ml),
with each concentration assayed in 84 replicates on a single real-time plate. To
determine the inter-plate variance of the estimate of deletion level differences
between samples at a similar deletion level, the 10% and 80% deletion level DNA
samples (patients 1 and 6, respectively) were mixed in varying ratios to generate
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low deletion level (20–25%; n53, numbered A–C) and high deletion level (70–
80%; n53, numbered D–E) samples, which were analysed in 24 replicates
([DNA]PCR.1 pg/ml) on separate real-time plates (n53). The proportion of
deleted mtDNA was calculated from the MT-ND4 (wild-type molecules) and MT-
ND1 (total mtDNA) data.
Mitochondrial DNA copy number
Relative levels of mtDNA copy number were determined by real-time PCR using
singleplex Taqman assays designed to target the mitochondrial MT-ND1 gene (as
described in mtDNA deletion assay method) and the nuclear B2M gene (GenBank
accession number: NG_012920). Primers and probe for the B2M assay were as
follows: B2M forward primer 59-CCAGCAGAGAATGGAAAGTCAA-39 (gene
location n.8969-8990), B2M reverse primer 59-TCTCTCTCCA-
TTCTTCAGTAAGTCAACT-39 (n.9064-9037) and B2M probe 6FAM-59-
ATGTGTCTGGGTTTCATCCATCCGACA-39-MGB (n.9006-9032). Final B2M
primer and probe concentrations were 300 nM and 100 nM, respectively. Each
20 ml B2M reaction was supplemented with 3 mM MgCl2. To minimise pipetting
error, DNA was added to each well in 5 ml volumes. Standard curves were
included for analysis of data. MT-ND1 and B2M Taqman assays were analysed
sequentially on the same real time machine; samples were located in the same
wells on paired plates to minimise well-to-well error. To determine intra- and
Table 1. Clinical details of patients with single, large-scale mtDNA deletions and control individuals.
Subject Sex Age1
Clinical
features
MtDNA deletion
breakpoints2
MtDNA
deletion
level
Patient 13 F 40 CPEO 9486–13723 84%
Patient 2 M 41 CPEO,
epilepsy
8469–13447 69%
Patient 34 M 40 CPEO 8289–13041 48%
Patient 4 M 37 CPEO,
diplopia,
myopathy,
fatigue
7637–15676 38%
Patient 5 F 33 CPEO,
myopathy,
fatigue
9754–15567 20%
Patient 6 M 38 CPEO 7845–15440 6%
Control 1 M 27 - - -
Control 2 M 45 - - -
Control 3 M 58 - - -
CPEO, chronic progressive external ophthalmoplegia.
1Age at time of biopsy.
2GenBank accession number NC_012920.1.
3Patient 1 published in [7].
4Patient 3 published in [8].
doi:10.1371/journal.pone.0114462.t001
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inter-plate variance, two control skeletal muscle DNA samples with high
(approximately two-fold) relative copy number difference and of equivalent
concentration were mixed in varying ratios to generate samples of progressively
increasing mtDNA copy number (numbered S1 to S5). These five samples were
analysed in duodecuplicate on each B2M and MT-ND1 real-time PCR plate at
varying DNA concentrations; each plate was performed in quadruplicate. To
ensure the sample quantification cycles (Cq) for both reactions were within an
optimal detection range of 17 to 33, final PCR DNA concentrations differed by an
order of magnitude between the mitochondrial (20 pg/ml.[DNA]PCR.0.3 pg/ml)
and nuclear (0.6 ng/ml.[DNA]PCR.10 pg/ml) reactions. The MT-ND1/B2M copy
number ratio was calculated for each sample well on each plate, yielding 12
replicate values per sample per MT-ND1/B2M plate pair. The relative copy
numbers of samples S2 to S5 compared to sample S1 were calculated from these
data, resulting in 48 independent sample comparisons per MT-ND1/B2M plate
pair.
Statistical analysis and data reporting
For each analysis, severe outliers, defined as data points more than three times the
interquartile range below or above the lower and upper data quartiles,
respectively, were removed from the data prior to further analysis. This approach
was adopted in order to remove any operator-induced error in the data. It
resulted in the removal of 31 values from the 2352 total replicates (1.3%)
generated for determining the intra-plate deletion level variation, 6 values from
the 432 replicates (1.4%) obtained for assessing the inter-plate mtDNA deletion
level variation and 17 values from the 720 replicates (2.4%) used for calculating
the mtDNA copy number assay variation.
Intra-plate variance, for both the mtDNA deletion level and copy number
assays, was quantified by the standard deviation of the replicates on each plate and
bias-corrected [21]. The large number of replicates generated with the deletion
assay permitted the use of bootstrapping to calculate 95% confidence intervals for
the standard deviation [22]. Inter-plate variance was assessed by taking the
estimate of each measure (either deletion level or relative copy number difference)
from each plate and calculating the standard deviation of these values, which were
also bias-corrected. The standard deviation estimates were further adjusted to
correct for the intra-plate variance by subtracting the estimated intra-plate
variance divided by the number of replicates per plate. Bootstrapping was
performed in MATLAB Release 2012A (The MathWorks Inc., Natick, MA). SAS
version 9.2 (Cary, NC) was used for all other statistical analyses. PROC GLM was
used to perform linear regression to investigate the relationship between assay
variation, DNA concentration (Cq), and mtDNA deletion level/copy number.
Where linear regression is used the correlation coefficient (r), number of
independent samples (n) and P-value are reported. Parameter estimates are
reported separately where appropriate. Where the relationship between variables
is non-linear, the Spearman’s rho (Spearman’s r), n and P-value are reported.
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The number of repeat plates (with 3 or 6 replicates per sample per plate)
required to observe a given deletion level or relative copy number difference was
calculated from the estimated inter- and intra-plate standard deviations using a
two tailed t-test at b50.80 and a50.05. For the MT-ND1/MT-ND4 assay, only
data obtained from the high DNA concentration reactions were used, exploiting
the observed linear relationship between standard deviation and target deletion
level. For the mtDNA copy number assay, the standard deviations at low,
moderate and high PCR DNA concentrations were used to estimate the number
of plates required. The standard deviations are reported in percentage points for
the deletion level assay. For the copy number assay, the error is linearly related to
the log of the mtDNA copy number values, and thus the geometric standard
deviation is reported; equivalent scale factors (expressing percentage change) were
calculated by taking the exponential of the geometric standard deviation.
Results
Quantification of variability within the MT-ND1/MT-ND4 and MT-ND1/B2M
real time PCR assays requires measurement of both the precision and the accuracy
of the assays. Intra-plate variability is a straightforward estimate of the precision.
Similarly, inter-plate variability can be used to estimate the accuracy of the assay,
though any estimate will be inflated by intra-plate variation and this must be
taken into account. The intra- and inter-plate variances in both assays were
determined here across a range of DNA concentrations and mtDNA deletion/copy
number levels.
Intra-plate variability of the mitochondrial MT-ND1/MT-ND4
deletion assay is dependent on DNA concentration and
heteroplasmy level
MT-ND1/MT-ND4 deletion assay intra-plate variance was assessed using DNA
samples from six patients (patients 1–6) harbouring single, large-scale mtDNA
deletions with varying MT-ND4 deletion levels (6–84%). This analysis identified
two factors that were affecting the precision of the assay, namely DNA
concentration and level of mtDNA deletion heteroplasmy (Figure 1). For each
DNA sample analysed, the precision of the mtDNA deletion measurement
decreased consistently with decreasing DNA concentration (Spearman’s r50.83,
n528, P,0.0001) and assay variability became notably high at DNA concentra-
tions associated with Cq.30 (equivalent to a final PCR DNA concentration of less
than 0.01 pg/ml). Furthermore, the precision of the MT-ND1/MT-ND4 assay
decreased with decreasing sample deletion levels. Specifically, at high DNA
concentrations (CqMT-ND1,25; [DNA]PCR.0.3 pg/ml), a linear inverse relation-
ship between the level of mtDNA heteroplasmy in a sample and assay variability
was identified (n57, r520.993, P,0.0001; Figure 2). A similar linear relationship
was observed at moderate DNA concentrations (25,CqMT-ND1,30; n510,
Accurate mtDNA Quantification in Skeletal Muscle
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Figure 1. Effects of DNA concentration and heteroplasmy level on the accuracy of theMT-ND1/MT-ND4
deletion assay. Percentage standard deviations of DNA sample replicates (n584) are represented relative to
average Cq for homogenate skeletal muscle DNA samples (n56) varying in MT-ND4 deletion levels from 10–
80%. Confidence intervals at 95% are shown. The y axis is log10 scaled.
doi:10.1371/journal.pone.0114462.g001
Figure 2. Relationship betweenMT-ND1/MT-ND4 deletion assay variability and heteroplasmy level at high, moderate and low DNA concentrations.
For all panels, percentage point standard deviations of DNA sample replicates (n584) are displayed relative to deletion heteroplasmy in homogenate
skeletal muscle samples. Regression lines (solid) and 95% confidence intervals for the regression lines (dotted lines) are shown. A Linear relationship (n57,
r520.997, P,0.0001) between the percentage MT-ND4 deletion level (heteroplasmy) and MT-ND1/MT-ND4 deletion assay variation at high DNA
concentrations (average Cq values for all DNA samples below 25). B A similar linear relationship (n510, r520.831, P50.0029) is seen at moderate DNA
concentrations (average Cq values for all DNA samples between 25 and 30). C At low DNA concentrations (average Cq values for all DNA samples above
30) there is not a significant linear trend (n511, r520.209, P50.5368).
doi:10.1371/journal.pone.0114462.g002
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r520.824, P50.0033). At low DNA concentrations (CqMT-ND1.30) no linear
relationship was apparent (n511, r520.326, P50.3005).
Inter-plate variability of the mitochondrial MT-ND1/MT-ND4
deletion assay is low
In view of the effect of heteroplasmy on intra-plate variability, inter-plate variance
was assessed on two sets of DNA samples at high DNA concentration, one set
harbouring low levels of deletion (20–25%, samples A–C) and the other set high
levels (70–80%, samples D–F) (Figure 3). Independent values for the differences
in deletion level between sets of two samples (A versus B and B versus C, D versus
E and E versus F) were calculated for each replicate (n524) per plate (n53). The
true deletion level difference was estimated for each pair of samples from the
mean of all replicates across all plates. The deviation of these independent values
from the best estimate of the true deletion level difference was then determined.
The estimate for the inter-plate standard deviation at low deletion level was
0.496% and 0.4795% at high deletion level, with a pooled estimate of 0.485%
using all samples. Interestingly, the inter-plate variation was not found to be
substantially affected by the deletion level of the samples under comparison.
Although Figure 3 suggests that the low deletion level samples exhibited higher
inter-plate variation, this extra variability is almost entirely attributable to the
higher intra-plate variation.
DNA concentration also affects the intra-plate variability of the
mtDNA copy number assay
Five DNA samples (S1–S5) of varying mtDNA levels were used to assess the
variability of the MT-ND1/B2M assay. Replicate MT-ND1/B2M copy number
ratios (n512) were generated for each sample from 4 replicate plate pairs at
different DNA concentrations. Independent relative copy number values were
then calculated for each plate pair replicate of S2, S3, S4 and S5 compared to S1.
As relative copy number is a ratio, intra-plate and inter-plate variability were
quantified as geometric standard deviations. Similar to the mtDNA deletion assay,
intra-plate variability in the mtDNA copy number assay was dependent on Cq,
with variability increasing with increasing Cq (Spearman’s r50.81, n548,
P,0.0001; Figure 4). Intra-plate variability was not however related to copy
number ratio with dilute DNA samples (CqMT-ND1.25, [DNA]PCR,0.3 pg/ml;
r50.031, n516, P50.9084), moderate DNA concentrations (CqMT-ND1524,
[DNA]PCR50.6 pg/ml; r50.167, n516, P50.5373) or concentrated DNA samples
(CqMT-ND1,20, [DNA]PCR.10 pg/ml; r50.423, n516, P50.1025). The estimates
for the intra-plate geometric standard deviation are 0.0686 (corresponding scale
factor 1.071; high DNA concentration), 0.0834 (1.087; moderate) and 0.181
(1.199; low).
Inter-plate variability was not significantly related to Cq (Spearman’s r50.26,
n512, P50.2578), nor was there a significant linear relationship between inter-
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plate variability and mtDNA copy number ratio (r50.284, n512, P50.3685). The
estimate of inter-plate geometric standard deviation calculated from all samples is
0.0305 (scale factor 1.031), which is lower than the intra-plate standard deviation
at all DNA concentration levels.
Recommendations on replicate numbers for the mtDNA deletion
and copy number assays
Based on the data presented, it is possible to determine the numbers of replicates
of samples and real-time PCR plates required to achieve specific levels of accuracy
with the two mtDNA assays. Recommendations on the number of MT-ND1/MT-
ND4 sample and plate replicates necessary to confidently determine a given
heteroplasmy difference (1–20%) between two homogenate skeletal muscle DNA
samples are provided in Table 2. Table 3 outlines replicate numbers necessary to
identify a specific difference (10–50%) in mtDNA copy number between two
DNA samples at different DNA concentrations. The methodology to calculate
sample sizes and all the required parameters for determining replicate numbers at
other mtDNA deletion/copy number levels are provided in File S1.
Figure 3. Inter- and intra-plate variability in the measurement of MT-ND4 deletion level differences
between DNA samples. Independent values for the difference in deletion level (in percentage points)
between two homogenate skeletal muscle DNA samples harbouring either low (20–25%; samples A–C) or
high (70–80%; samples D–F) MT-ND4 deletion levels are shown for each sample replicate (n524; grey dots)
per replicate real time PCR plate (n53). Data are normalised by subtracting the best estimate of the true
deletion level difference, determined as the mean of all replicates on all plates. Mean values for each dataset
are displayed (horizontal bars). The mean values from individual plates are within 1% of the actual deletion
level, though individual replicates vary by up to ¡9% at low deletion level and ¡6% at high deletion level.
doi:10.1371/journal.pone.0114462.g003
Accurate mtDNA Quantification in Skeletal Muscle
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Discussion
The purpose of this study was to comprehensively assess the variability present
within two quantitative real-time PCR assays, the MT-ND1/MT-ND4 multiplex
mtDNA deletion assay [11] and a MT-ND1/B2M singleplex mtDNA copy number
assay [19], and provide guidelines for achieving accurate and reliable
heteroplasmy and copy number measurements in homogenate skeletal muscle
samples across a range of experimental conditions (DNA concentration and
deletion level/relative copy number). The precision of both assays was found to be
dependent on DNA concentration; mtDNA deletion level, but not relative copy
number, also affected assay variability. Accurate mtDNA measurements are
essential for detecting small differences in mtDNA quantity and integrity, critical
for improving our understanding of mtDNA disease progression and evaluating
the efficiency of novel therapeutic approaches. To the best of our knowledge, this
is the first study to detail necessary sample and real-time PCR plate replicates to
determine a given difference in mtDNA deletion levels and copy number.
Figure 4. Inter- and intra-plate variability in the measurement of mtDNA copy number differences
between DNA samples. Replicate (n512) MT-ND1/B2M copy number ratios were obtained for five
homogenate skeletal muscle DNA samples of varying mtDNA copy number (samples S1 to S5) on each of
four replicate MT-ND1/B2M real time PCR plate pairs at different DNA concentrations (low – corresponding to
an average CqMT-ND1 of 19 and an average CqB2M of 27, moderate - CqMT-ND1524 and CqB2M530, high - CqMT-
ND1525.5 and CqB2M533). Independent relative copy number values were then calculated for each replicate
of S2, S3, S4 and S5 compared to S1 for each MT-ND1/B2M plate. Intra-plate standard deviations are shown
as circles (relative copy number values: S2:S151.10 (green circles), S3:S151.25 (blue circles), S4:S151.50
(orange circles), S5:S151.9 (red circles)). Inter-plate standard deviations are shown as grey crosses. As
relative copy number is a multiplicative relationship, geometric standard deviations are shown.
doi:10.1371/journal.pone.0114462.g004
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Table 2. Number of plates required to identify a given heteroplasmy difference between two homogenate skeletal muscle DNA samples at various MT-ND4
deletion levels with the MT-ND1/MT-ND4 Taqman deletion assay.
Detectable difference in mtDNA deletion level
1% 2% 5% 10% 20%
Replicates per
plate
Deletion
Level SD P n P n P n P n P n
3 10% 1.83% 0.80 54 0.82 15 0.89 4 ..99 3 ..99 2
3 20% 1.64% 0.81 44 0.81 12 0.95 4 0.84 2 ..999 2
3 30% 1.45% 0.81 35 0.83 10 0.88 3 0.91 2 ..999 2
3 40% 1.27% 0.81 27 0.83 8 0.94 3 0.95 2 ..999 2
3 50% 1.09% 0.81 20 0.82 6 0.98 3 0.98 2 ..999 2
3 60% 0.92% 0.82 15 0.85 5 ..99 3 ..99 2 ..999 2
3 70% 0.76% 0.84 11 0.87 4 0.89 2 ..999 2 ..999 2
3 80% 0.62% 0.85 8 0.84 3 0.96 2 ..999 2 ..999 2
3 90% 0.52% 0.85 6 0.93 3 0.99 2 ..999 2 ..999 2
6 10% 1.34% 0.81 30 0.84 9 0.92 3 0.94 2 ..999 2
6 20% 1.21% 0.80 24 0.81 7 0.96 3 0.97 2 ..999 2
6 30% 1.08% 0.81 20 0.82 6 0.98 3 0.99 2 ..999 2
6 40% 0.96% 0.81 16 0.82 5 ..99 3 ..99 2 ..999 2
6 50% 0.84% 0.83 13 0.91 5 0.83 2 ..999 2 ..999 2
6 60% 0.73% 0.82 10 0.89 4 0.90 2 ..999 2 ..999 2
6 70% 0.64% 0.83 8 0.82 3 0.95 2 ..999 2 ..999 2
6 80% 0.56% 0.80 6 0.90 3 0.98 2 ..999 2 ..999 2
6 90% 0.50% 0.87 6 0.95 3 0.99 2 ..999 2 ..999 2
Standard deviation (SD) is expressed in percentage points.
Actual power (P) and number of plates (n) are shown. Cq,23 ([DNA]PCR.1 pg/ml).
doi:10.1371/journal.pone.0114462.t002
Table 3. Number of MT-ND1 and B2M real time PCR plates required to detect a specific relative difference in mtDNA copy number between two
homogenate skeletal muscle DNA samples for a given number of replicate sample wells.
Detectable difference in mtDNA copy number
10% 20% 30% 40% 50%
Replicates
per plate DNA Concentration P n P n P n P n P n
3 High 0.80 6 0.88 3 0.99 3 0.87 2 0.95 2
3 Moderate 0.84 8 0.94 4 0.97 3 1.00 3 0.90 2
3 Low 0.80 25 0.82 8 0.87 5 0.92 4 0.88 3
6 High 0.83 5 0.95 3 0.81 2 0.94 2 0.98 2
6 Moderate 0.85 6 0.91 3 1.00 3 0.90 2 0.96 2
6 Low 0.81 16 0.87 6 0.91 4 0.91 3 0.97 3
Each cell defines the number of plates (n) and actual power (P; minimum power 0.8 at a50.05) for a two sample t-test to detect, with the specified number of
sample replicates per plate, a given percentage difference in mtDNA copy number. Estimates are calculated at high (approximate CqMT-ND1 of 19
([DNA]PCR520 pg/ml) and CqB2M of 27 ([DNA]PCR50.6 ng/ml)), moderate (approximate CqMT-ND1 of 24 ([DNA]PCR50.6 pg/ml) and CqB2M of 30
([DNA]PCR50.1 ng/ml)) and low (approximate CqMT-ND1 of 25 ([DNA]PCR50.3 pg/ml) and CqB2M of 33 ([DNA]PCR510 pg/ml)) PCR DNA concentration levels.
doi:10.1371/journal.pone.0114462.t003
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There are many published methods for quantifying mtDNA, all targeting
different mitochondrial and nuclear genomic regions and relying on different real-
time chemistries [12, 14–17, 23, 24]. However, few researchers have reported how
the variability of their assays is affected by the experimental conditions. Until now,
only a cursory assessment of the reproducibility of our MT-ND1/MT-ND4
deletion assay had been carried out [11], which, coupled to a growing lack of
confidence in the assay’s ability to accurately measure deletion levels below 20–
30% [9, 25], has been limiting the scope of the assay. The additional sample
processing and pipetting associated with the singleplex approach of the mtDNA
copy number assay also necessitate a comprehensive analysis of this assay’s
intrinsic error. These particular assays were chosen for evaluation as we believe
they offer versatility and flexibility with regards to mtDNA deletion level and copy
number quantification. The deletion assay targets a highly conserved MT-ND1
genomic region as well as an mtDNA region absent in over 95% of all reported
deleted molecules (MT-ND4), a design which permits the detection of the vast
majority of mtDNA deletions described to date [26]. Furthermore, the assay can
be applied to both homogenate tissue and single cell investigations
[7, 9, 11, 18, 27, 28]. The mtDNA copy number assay uses Taqman chemistry to
ensure specificity and maintain compatibility with the deletion assay, enabling
MT-ND1 data to be shared between both quantification assays. The assay exploits
a single-copy nuclear gene, B2M, which, unlike other often used reference genes
(e.g. ACTB [29] or 18S rRNA [30]), has low sequence variability ([12]; Table S1)
and permits inter-patient comparisons. Finally, the singleplex design not only
circumvents the issue of reagent saturation associated with multiplexing, but also
provides the added benefit of allowing the sample DNA concentration to be
modified in order to maintain nuclear quantification cycles below 30.
The ability to optimise the sample DNA concentration is particularly important
in view not only of the recent publication by Sochivko et al., which describes the
dependency of real-time PCR measurement error on DNA concentration [20],
but also of our present data, which similarly demonstrate how decreasing sample
concentration increases variability in both the MT-ND1/MT-ND4 and MT-ND1/
B2M assays. With homogenate skeletal muscle samples, we highly recommend
final DNA concentrations in B2M reactions be kept above 0.1 ng/ml (equivalent to
CqB2M,30), whilst in the MT-ND1/MT-ND4 reactions, final DNA concentrations
between 0.1 ng/ml and 0.3 pg/ml (equivalent to 16.5,CqMT-ND1,25) are optimal.
In our experience, 10 mg of biopsy tissue provide ample material to perform the
necessary numbers of repeats required for the highest level of accuracy we believe
to be achievable with both mtDNA assays.
Much interest is now placed on elucidating molecular events at a single cell
level. Although beyond the scope of this study, the level of accuracy to be expected
in single cell measurements can be extrapolated. Based on the assumption a single
cell contains 6.5 pg genomic DNA, it should be possible to perform up to 10
repeat measurements of MT-ND1 and MT-ND4 with a final PCR DNA
concentration approximating 0.03 pg/ml, achieving Cq values just below 30, the
critical threshold above which assay variation increases exponentially (although
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the MT-ND4 Cq value could be higher depending on the level of mtDNA deletion
present and the mtDNA copy number will vary depending on cell type). Single cell
analyses will inevitably be limited by a higher level of noise within the data and
small differences in deletion level or copy number will not be accurately detected
with current real-time PCR technology.
Consistent with the preliminary assessment of the multiplex MT-ND1/MT-
ND4 assay [11], we have confirmed a relationship between sample heteroplasmy
and assay accuracy; as deleted mtDNA levels decrease, measurement error also
increases. Despite this increased error, we have confirmed the MT-ND1/MT-ND4
assay can be used to detect deletion levels below the previously published 20–30%
cut-off threshold [9, 25], with an accuracy comparable to that achieved with high
deletion load samples, providing sufficient replicates are included in the analysis.
Contrary to the observed effect of heteroplasmy on the deletion assay, variation
in the mtDNA copy number assay was found to be independent of the relative
difference in mtDNA abundance, within the range investigated (a maximum of
approximately 2-fold difference). Furthermore, despite expectations that the extra
DNA dilution for the MT-ND1 measurement may have introduced an
unacceptable level of experimental error into the procedure, the inter-plate
variability (1.031 scale factor), which would incorporate this error, was found to
be lower than the intra-plate variability at all DNA concentration levels. This is in
contrast to reports from Malik and colleagues, who described a ‘dilution bias’
when measuring blood mtDNA copy number at different DNA concentrations
[31]. Analysis of a different tissue, skeletal muscle, which harbours up to two
orders of magnitude more mtDNA than blood, and the development of a rigorous
protocol for diluting the DNA samples and performing the real-time PCR analysis
may in part explain how dilution effects were minimised in this study.
In summary, we have devised guidelines regarding the number of sample and
real-time PCR plate replicates necessary for accurately and reliably determining a
given difference in mtDNA integrity and abundance in homogenate skeletal
muscle samples at different DNA concentrations and mtDNA deletion/copy
number levels. Researchers routinely only include three sample replicates in any
quantitative PCR analysis and only perform up to three replicate plates; it is clear
from this study however that this approach is not always valid, in particular at low
level deletion and low DNA concentration with the MT-ND1/MT-ND4 assay and
with the mtDNA copy number assay in general. By defining the limits of detection
of these two assays, it should now be possible to investigate, with greater accuracy,
the molecular consequences of novel therapeutic approaches for mitochondrial
disease. Moreover, we believe these recommendations will also help advance our
current understanding of the clinical progression of mitochondrial pathologies.
Supporting Information
Figure S1. DNA integrity demonstrated by agarose gel electrophoresis. In order
to ensure storage at 4 C˚ did not impact on the integrity of the DNA, available
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DNA samples (50–100 ng) were analysed by electrophoresis through a 1% agarose
gel before (1) and after (2) storage for up to a month at 4 C˚. L, Promega 1 kb
DNA ladder.
doi:10.1371/journal.pone.0114462.s001 (DOC)
Table S1. Sequence variability of commonly used real-time PCR reference
genes. Data obtained from NCBI dbSNP database (Sherry et al. (2001) Nucleic
Acids Res. 29(1):308-11) in September 2014.
doi:10.1371/journal.pone.0114462.s002 (DOC)
File S1. Methodology for calculating replicate sample and plate numbers.
doi:10.1371/journal.pone.0114462.s003 (DOC)
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